Formats available
You can view the full content in the following formats:
References
1.
Sestak I, Buus R, Cuzick J et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4(4), 545–553 (2018).
2.
Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726–3734 (2006).
3.
Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817–2826 (2004).
4.
Geyer CE, Tang G, Mamounas EP et al. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer 4, 37 (2018).
5.
Filipits M, Rudas M, Jakesz R et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17(18), 6012–6021 (2011).
6.
Filipits M, Nielsen TO, Rudas M et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin. Cancer Res. 20(5), 1298–1305 (2014).
7.
Filipits M, Dubsky P, Rudas M et al. Prediction of distant recurrence using EndoPredict among women with ER+, HER2- node-positive and node-negative breast cancer treated with endocrine therapy only. Clin. Cancer Res. 25(13), 3865–3872 (2019).
8.
Dowsett M, Sestak I, Lopez-Knowles E et al. Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J. Clin. Oncol. 31(22), 2783–2790 (2013).
9.
Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene Recurrence Score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 28(11), 1829–1834 (2010).
10.
Buus R, Sestak I, Kronenwett R et al. Comparison of EndoPredict and EPclin with Oncotype DX Recurrence Score for prediction of risk of distant recurrence after endocrine therapy. J. Natl Cancer Inst. 108(11), (2016).
11.
Pan H, Gray R, Braybrooke J et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377(19), 1836–1846 (2017).
12.
Hannouf MB, Zaric GS, Blanchette P et al. Cost–effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer. Pharmacogenomics J. (2019) (Epub ahead of print).
13.
Hochheiser L, Hornberger J, Turner M, Lyman GH. Multi-gene assays: effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer. J. Comp. Eff. Res. 8(5), 289–304 (2019).
14.
Fallowfield L, Matthews L, May S, Jenkins V, Bloomfield D. Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing. Psychooncology 27(4), 1264–1269 (2018).
15.
Andre F, Ismalia N, Henry NL et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update – integration of results from TAILORx. J. Clin. Oncol. 37(22), 1956–1964 (2019).
16.
Sparano JA, Gray RJ, Ravdin P et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N. Engl. J. Med. 380(25), 2395–2405 (2019).
17.
Sparano JA, Gray RJ, Makower DF et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379(2), 111–121 (2018).
18.
Early Breast Cancer Trialists' Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814), 432–444 (2012).
19.
Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26(5), 721–728 (2008).
Information & Authors
Information
Published In
Pages: 1261 - 1263
PubMed: 31739684
Copyright
© 2019 Hochheiser et al. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 12 July 2019
Accepted: 5 September 2019
Published online: 19 November 2019
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Letter in reply. (2019) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2019-0095
Export citation
Select the citation format you wish to export for this article or chapter.